MDxHealth misses Q3 revenue target, suspends 2026 guidance
MDxHealth reported Q3 revenue of $22.7M, matching last year, and suspended 2026 guidance of $110-115M. Test volume decreased 11% YoY for tissue-based tests but increased for liquid-based tests. The company cited sales force turnover as a factor, with CEO McGarrity noting disruptions from Resolve mdx discontinuation. MDxHealth has $31.7M in cash as of Q3 2026.
How this was made
The 30-second read
Why it matters
The key tradable change is the suspension of full-year 2026 revenue guidance, signaling forecast uncertainty tied to unexpected sales force turnover after Resolve mdx discontinuation. The company will provide corrective-action details with full Q3 results on Nov 12.
Market read
Investors must reassess 2026 revenue expectations and near-term positioning ahead of the Nov 12 full Q3 results, where corrective actions may clarify the path back to guidance.
What to watch
Liquid-based test volume is described as much higher than the prior-year quarter, which could partially offset tissue-based declines if sustained.
Background
MDxHealth is a precision diagnostics company providing molecular diagnostic tests for prostate cancer and other urologic diseases.
Ticker impact
MDxHealth preliminarily reports Q3 revenue of about $22.7M and suspends its 2026 revenue guidance of $110-115M due to sales force turnover.
Likely downward pressure as investors reprice uncertainty around 2026 revenue after the guidance suspension.
The article discloses a guidance suspension plus specific operational drivers (unexpected sales force turnover after Resolve mdx discontinuation) and preliminary revenue/test-volume figures.
Market effects
Adds to read-through risk for precision diagnostics names where sales-force disruption can quickly impair test volumes and guidance credibility.
Limited, company-specific impact for US small-cap biotech/diagnostics sentiment.
Low, no cross-border deal or regulatory action described.
Counterpoint
The company attributes turnover to Resolve mdx discontinuation and aggressive recruiting, implying the disruption could be temporary if corrective actions restore sales coverage.
Key entities
- companyMDxHealth SA
Precision diagnostics company reporting preliminary Q3 revenue and suspending 2026 guidance.
- personMichael K. McGarrity
CEO who attributed sales force turnover to aggressive recruiting after Resolve mdx discontinuation.
